معرفی
Rebecka Hultgren is an active Adjunct Professor and Head of Department at Karolinska Institutet, affiliated with the Department of Molecular Medicine and Surgery (K1 MMK) and Ulf Hedin's research group in Vascular Surgery. Her work spans clinical and translational vascular research with a focus on abdominal aortic aneurysms (AAA) and aortic dissection, utilizing population-based registries, randomized trials, and biomechanical modeling to address critical gaps in disease management.
Her research interests center on vascular disease pathophysiology, particularly AAA growth prediction, sex-specific rupture risks, and psychological comorbidities. She investigates biomechanical factors like sealing zone failure and peak wall rupture index, explores molecular mechanisms including microRNA biomarkers and vascular calcification, and pioneers eHealth interventions for anxiety management. Her work emphasizes cardiovascular risk optimization, hereditary screening, and the impact of comorbidities such as kidney disease and cancer on aortic conditions.
Recent publications (2024-2025) reveal three dominant trends: advanced biomechanical modeling for rupture prediction, gender-specific outcome disparities in aneurysm repair, and psychological/cardiovascular risk management integration. Key journals include Journal of Vascular Surgery and European Journal of Vascular and Endovascular Surgery, with studies frequently involving Swedish national registries and international collaborations like the PHAST trial.
While her profile indicates a Grants section, no specific funding details or student advisees were extracted from the provided text. Her leadership role and extensive publication record suggest active grant acquisition, particularly for clinical trials such as the TRAIN Health Awareness study and DAAAD screening project.
She operates within Ulf Hedin's research group at Karolinska Institutet, which focuses on molecular mechanisms of vascular diseases. The group utilizes advanced imaging (PET/CT), biomechanical analysis, and population health data to investigate aneurysm progression and treatment efficacy.
